Latest News about Phase 1 Trial
Recent news which mentions Phase 1 Trial
Do You Need A COVID-19 Booster Dose? Pfizer-BioNTech Submit Initial Data To Support Idea
August 16, 2021
From Benzinga
Histogen Shares Additional Emricasan Data From COVID-19 Study
August 16, 2021
Tickers
HSTO
From Benzinga
Equillium's Itolizumab Reduces Urine Protein In Lupus Patients
August 12, 2021
Tickers
EQ
From Benzinga
CohBar Stock Edges Higher As Mitochondria Based Therapeutic Shows Encouraging Action In Early-Stage NASH Trial
August 11, 2021
Tickers
CWBR
From Benzinga
Fulcrum Shares Are Trading Higher As Candidate For Inherited Blood Disorders Shows Proof Of Mechanism, Biology In Early-Stage Study
August 10, 2021
Tickers
FULC
From Benzinga
Exicure Shares Interim Cavrotolimod Data From Early-Stage Trial In Solid Tumor Patients
August 05, 2021
From Benzinga
Amgen Stops Phase 1 For One BiTE Molecule While Resuming Dosing For Another, Plans Second Drug Substance Plant
August 04, 2021
Tickers
AMGN
From Benzinga
Angion Biomedica Shares Moving Higher On Encouraging Results From Early Stage Trial Of Fibrotic Disease Candidate
August 03, 2021
Tickers
ANGN
From Benzinga
Avidity Biosciences Shares Gain As Its Oligonucleotide Candidate Enters Early-Stage Trial In Muscle Wasting Disorder
August 02, 2021
Tickers
RNA
From Benzinga
Fusion Pharma Stock Is Trading Higher As FDA Clears Early-Stage Study For Radiopharmaceutical In Neck, Bladder Cancers
July 29, 2021
Tickers
FUSN
From Benzinga
Dicerna Posts Updated Data From Belcesiran Early-Stage Study For Genetic Liver Disease
July 21, 2021
Tickers
DRNA
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free